Sign up
Quantellect · Analysts · Analyst Profile
Analyst Score Rank#36 of 589

Mayank Mamtani

B. Riley Securities · Equity Research Analyst
ProvisionalRating since 2020No new ratings since Oct 2025

Analyst rating accuracy & track record

Mayank Mamtani is an equity research analyst at B. Riley Securities. Quantellect has scored 39 of their stock calls across 25 companies. Their picks beat their sector 49% of the time over the next 12 months, and their price targets were reached 41% of the time within a year.

Win % vs sector
49%
PT Hit % (12mo)
41%
Avg sector-excess
+7.2%
Scored calls
39
Tickers
25
Tier
Provisional

Track record

Quantellect has scored 39 of Mayank Mamtani's stock calls across 25 companies, dating back to 2020. Their rated stocks beat their own sector 49% of the time over the next 12 months. On a typical call, a Mamtani pick returned +7.2% more than its sector over the following year.

Of the scored calls, 39 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
ZYMEZymeworks Inc. Common Stock
Buy$30.00Oct 2025+17.7%Hit
SNDXSyndax Pharmaceuticals Inc
Buy$33.00Oct 2025−8.4%Miss
MDGLMadrigal Pharmaceuticals Inc
Buy$560.00Sep 2025−12.6%Hit
NKTRNektar Therapeutics
Buy$105.00Sep 2025−29.2%Hit
TGTXTG Therapeutics Inc
Buy$55.00Sep 2025+49.2%Hit
TGTXTG Therapeutics Inc
Buy$55.00Sep 2025+49.2%Hit
TBPHTheravance Biopharma Inc
Buy$28.00Sep 2025−5.8%Miss
ACTUActuate Therapeutics, Inc. Common stock
Buy$20.00Aug 2025−106.2%Miss
ACTUActuate Therapeutics, Inc. Common stock
Buy$20.00Aug 2025−106.2%Miss
INKTMink Therapeutics Inc
Buy$43.00Aug 2025−52.5%Miss
TRVITrevi Therapeutics Inc
Buy$16.00Aug 2025+121.0%Hit
ALTAltimmune Inc
Buy$18.00Aug 2025−49.1%Miss
NKTRNektar Therapeutics
Buy$85.00Jul 2025+186.4%Hit
AGENAgenus Inc
Buy$8.00Jul 2025−57.5%Miss
MNOVMediciNova Inc
Buy$5.00Jun 2025−12.2%Miss
MDGLMadrigal Pharmaceuticals Inc
Buy$460.00May 2025+62.6%Hit
TRVITrevi Therapeutics Inc
Buy$20.00Mar 2025+60.4%Miss
DNLIDenali Therapeutics Inc
Buy$35.00Mar 2025+16.2%Miss
ARWRArrowhead Pharmaceuticals Inc
Buy$38.00Feb 2025+200.8%Hit
VKTXViking Therapeutics Inc
Buy$96.00Feb 2025−11.6%Miss
NKTRNektar Therapeutics
Buy$4.00Jan 2025+153.0%Hit
NVAXNovavax Inc
Buy$26.00Oct 2024−27.5%Miss
CNTACentessa Pharmaceuticals PLC ADR
Buy$33.00Sep 2024+19.2%Miss
ALTAltimmune Inc
Buy$20.00Aug 2024−30.9%Miss
TGTXTG Therapeutics Inc
Buy$34.00Aug 2024+51.3%Hit
Prev1
Go to

Mayank Mamtani: analyst track record FAQ

Is Mayank Mamtani a good stock analyst?

Yes, by track record. Mayank Mamtani ranks number 36 of 589 of the analysts Quantellect scores, with an Analyst Score of 72 out of 100. Past results do not guarantee future ones.

What is Mayank Mamtani's win rate?

Mayank Mamtani's win rate is 49%. Across 39 scored calls, their rated stocks beat their sector 49% of the time over the next 12 months. On a typical call they returned +7.2% more than the sector.

What stocks and sectors does Mayank Mamtani cover?

Mayank Mamtani covers 25 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Mayank Mamtani's price targets accurate?

Mayank Mamtani's price targets are reached within 12 months 41% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Mayank Mamtani's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Mayank Mamtani rank among Wall Street analysts?

Mayank Mamtani ranks number 36 of 589 by Analyst Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.